Ownership and insider activity for MDxHealth S.A. (MDXH): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool.
Price
| Price | $0.68 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | BE |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-13 | MVM Partners, LLC | P-Purchase | 2,202,643 | $1000K |
| 2026-05-18 | OConnell Brendan | |||
| 2026-03-18 | Bednarski Eric | |||
| 2026-03-18 | Bellano John | 20,000 | ||
| 2026-03-18 | Bellano John | 65,000 | $170K | |
| 2026-03-18 | Bellano John | 200,000 | $294K | |
| 2026-03-18 | McGarrity Michael | |||
| 2026-03-18 | McGarrity Michael | 50,000 | ||
| 2026-03-18 | McGarrity Michael | 186,875 | $490K | |
| 2026-03-18 | McGarrity Michael | 500,000 | $735K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.5M | $16.8M | $26.2M | $22.1M | $16.0M | $58.5M | $15.5M | $22.4M | $46.8M | $29.0M |
| Short-term Investments | 0 | 0 | 0 | $51000 | 0 | $89000 | $101000 | 0 | 0 | 0 |
| Receivables | $18.5M | $19.9M | $19.1M | $6.6M | $3.9M | $4.6M | $9.4M | $11.3M | $14.5M | $14.7M |
| Inventory | $1.5M | $1.9M | $1.8M | $1.2M | $2.3M | $1.9M | $2.3M | $2.8M | $3.9M | $6.7M |
| Total Current Assets | $51.5M | $39.3M | $47.9M | $30.9M | $23.1M | $66.6M | $29.1M | $38.2M | $66.9M | $53.4M |
| Property, Plant & Equipment | $2.3M | $2.6M | $2.1M | $2.5M | $3.7M | $5.0M | $7.9M | $9.9M | $13.0M | $14.7M |
| Goodwill | $1.1M | $1.1M | $1.1M | 0 | 0 | 0 | $35.9M | $35.9M | $35.9M | $38.9M |
| Intangible Assets | $12.8M | $15.5M | $14.4M | $7.3M | $5.1M | $3.4M | $46.2M | $44.3M | $40.6M | $39.4M |
| Total Assets | $67.7M | $58.5M | $65.5M | $40.6M | $31.9M | $75.1M | $119.1M | $129.1M | $157.3M | $148.0M |
| Accounts Payable | $7.5M | $8.1M | $6.5M | $5.0M | $5.3M | $7.5M | $10.2M | $8.8M | $8.0M | $10.3M |
| Short-term Debt | $430000 | $191000 | $147000 | $565000 | $2.8M | $4.4M | $616000 | $643000 | $324000 | $1.9M |
| Total Current Liabilities | $12.6M | $13.1M | $11.5M | $10.4M | $13.0M | $16.4M | $18.3M | $19.5M | $42.7M | $49.5M |
| Long-term Debt | $108000 | $147000 | 0 | $9.1M | $10.3M | $7.7M | $34.9M | $35.6M | $51.0M | $84.7M |
| Total Liabilities | $15.0M | $15.0M | $13.4M | $20.9M | $26.0M | $28.2M | $109.8M | $121.9M | $142.5M | $160.0M |
| Retained Earnings | -$98.8M | -$111.1M | -$143.5M | -$186.6M | -$215.3M | -$244.3M | -$288.3M | -$331.4M | -$369.5M | -$403.0M |
| Total Equity | $52.7M | $43.5M | $52.1M | $19.7M | $5.8M | $46.9M | $9.3M | $7.2M | $14.8M | -$12.1M |
| Total Debt | $538000 | $884000 | $526000 | $11.0M | $15.9M | $15.6M | $39.8M | $41.3M | $60.1M | $95.1M |
| Net Debt | -$30.0M | -$15.9M | -$25.7M | -$11.1M | -$82000 | -$43.0M | $24.2M | $18.9M | $13.3M | $66.1M |
| Working Capital | $38.9M | $26.2M | $36.4M | $20.5M | $10.1M | $50.2M | $10.9M | $18.6M | $24.2M | $3.9M |
Financial Health
| Debt / Equity | -7.86 |
| Current Ratio | 1.08 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.73 |
Profitability
| Return on Equity | 402.97% |
| Return on Invested Capital | -12.74% |
| Return on Assets | -17.67% |
| Gross Margin | 57.68% |
| Operating Margin | -16.59% |
| Net Margin | -32.17% |
Related companies: ACRS · ASMB · IMRX · NEO · QTRX · SI · SNWV
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of MDXH: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks